Ergebnisse einschränken

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Reichardt, P. ; Blay, J.-Y ; Gelderblom, H. ; Schlemmer, M. ; Demetri, G. D. ; Bui-Nguyen, B. ; McArthur, G. A. ; Yazji, S. ; Hsu, Y. ; Galetic, I. ; Rutkowski, P.

In: Annals of Oncology, 2012, vol. 23, no. 7, p. 1680-1687